本期推荐：研究者针对DLL3靶向治疗适用性不明确的问题，通过多中心1294例NEN队列分析，发现DLL3在NEC（64.0%）和肺类癌（41.5% ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's Innovent Biologics, hoping to bring a competitor to Amgen's recently ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...